Delirium and Heart Failure
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age60+
SponsorAin Shams University
About this trial
Biomarkers such as Systemic Immune-Inflammation Index (SII) and TG/Glucose Ratio (TyG) have shown promise in predicting delirium, reflecting the roles of inflammation and metabolic disturbances in its pathophysiology. This study aims to compare the predictive value of SII and the TyG ratio among other chemical and physiological biomarkers for diagnosing delirium and detecting its severity in older adults with heart failure. These biomarkers reflect different pathophysiological pathways implicated in delirium, including inflammation, cardiovascular stress, and metabolic dysfunction. By evaluating their individual and combined predictive abilities, this research seeks to identify potential tools for early identification of patients at high risk for delirium
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
cognitive impairment
Major Neurological Conditions: (e.g., stroke, traumatic brain injury).
Hematological diseases that affect platelet, neutrophil, and lymphocyte counts.
Cardiogenic Shock
Trial population
hospitalized older adults with heart failure
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Comprehensive Geriatric Assessment
Other interventionmultidimensional assessment of cognition, physical, function, mood, social status of the participants
the Confusion Assessment Method (CAM test) or CAM-ICU
Other interventionstandardized tool designed to quickly and accurately diagnose delirium by assessing four key features: acute mental change, inattention, and either disorganized thinking or altered consciousness. The original CAM is used for communicative patients on general wards, relying on conversation, while the CAM-ICU is adapted for critically ill, often non-verbal patients in the ICU, using non-verbal tasks and sedation scales. By providing a rapid, reliable method for identifying this often-missed condition, both tools trigger crucial medical interventions, helping to mitigate delirium's serious risks, including longer hospital stays, long-term cognitive decline, and increased mortality.
Delirium Rating Scale - Revised-98
Other interventionThe Delirium Rating Scale-Revised-98 (DRS-R-98) is a standardized, expert-rated clinical tool designed specifically to measure the severity of delirium and help distinguish it from other psychiatric disorders, such as dementia, depression, and schizophrenia. Unlike the CAM/CAM-ICU, which provides a simple "yes/no" diagnosis, the DRS-R-98 quantifies how severe a patient's delirium is at a given point in time and tracks changes in that severity over the course of the illness
blood biomarkers
Diagnostic testcomplete blood count(to obtain systemic inflammatory index) ,triglyceride (TG) and glucose, Liver and kidney function tests and serum electrolytes level
Treatment groups
100 Participants
are divided into 2 treatment groupsGroup A: cases4 interventions
Group B: controls3 interventions
Trial outcomes
Primary outcomes
1
the sensitivity and specificity of different biomarkers of delirium in heart failure older patient
assess sensitivity and specificity of the systemic inflammatory index (SII), Rate Pressure Product (RPP), and TG/glucose ratio in predicting delirium
Time frame
Within 24 hours of hospital admissionSecondary outcomes
1
in hospital morbidity
follow up cohort for possible complications like acute kidney injury, infections, or adverse drug events
Time frame
From enrollment to the hospital discharge about 6 weeks2
In hospital mortality
cohort follow up throughout hospital course and mortality recorded
Time frame
From enrollment to hospital discharge about 6 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: